创伤性胸主动脉破裂:腔内修复与开放手术的系统评价与Meta分析
本研究通过系统检索四大数据库至2018年7月,纳入21篇文章共1968例创伤性胸主动脉破裂患者,比较开放手术与TEVAR的临床结局。结果显示TEVAR组30天死亡率(7.9% vs 20%)和1年死亡率(8.7% vs 17%)更低,但1年再干预率更高(6% vs 0%),而截瘫、卒中及5年死亡率无显著差异。
要点
- TEVAR较开放手术降低30天死亡率(7.9% vs 20%,OR 2.94)。
- TEVAR组1年再干预率更高(6% vs 0%,OR 0.17)。
- 截瘫、卒中及5年死亡率两者无显著差异。
核心结论
- 对于创伤性胸主动脉破裂,TEVAR较开放手术住院死亡率更低且围手术期结局满意,1年生存更优但再干预率更高。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Embase、Scopus和Ovid数据库至2018年7月,纳入21篇文章共1968例患者,其中TEVAR组578例(29%),开放手术组1390例(71%)。
主要发现
- TEVAR组与开放手术组30天死亡率分别为7.9%和20%(OR 2.94,95%CI 1.92-4.49,P<.00001)。
- 1年死亡率TEVAR组8.7%,开放手术组17%(OR 2.11,95%CI 0.99-4.52,P=.05)。
- 截瘫率TEVAR组1.4%,开放手术组2.3%(OR 1.27,95%CI 0.59-2.70,P=.54);卒中率分别为1%和0.5%(OR 0.63,95%CI 0.18-2.18,P=.46)。
- 5年死亡率TEVAR组23%,开放手术组17%(OR 0.07,95%CI -0.07至0.20,P=.33)。
- 1年再干预率TEVAR组6%,开放手术组0%(OR 0.17,95%CI 0.03-0.96,P=.04)。
临床怎么用
- 在创伤性胸主动脉破裂中,TEVAR可优先考虑以降低围手术期死亡风险,但需告知再干预可能性较高并计划随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to compare clinical outcomes between open repair and thoracic endovascular aortic repair (TEVAR) in traumatic ruptured thoracic aorta. METHODS: A comprehensive search was undertaken of the four major databases (PubMed, Embase, Scopus, and Ovid) to identify all published data comparing open vs endovascular repair. Databases were evaluated to July 2018. Odds ratios (ORs), weighted mean differences, or standardized mean differences and their 95% confidence intervals (CIs) were analyzed. The primary outcomes were stroke, paraplegia, and 30-day mortality rates; secondary outcomes were requirement for reintervention and 1-year and five-year mortality rates. RESULTS: A total of 1968 patients were analyzed in 21 articles. TEVAR was performed in 29% (n = 578) and open repair in 71% (n = 1390). TEVAR and open repair did not differ in the mean age of patients (42.1 ± 14 years vs 44.1 ± 14 years; P = .48). There was no difference in duration of intensive care and total hospital stay between TEVAR and open repair groups (12.7 ± 11.1 days vs 12.6 ± 8 days [P = .35] and 27.5 ± 14.6 days vs 25.9 ± 11 days [P = .80], respectively). Similarly, no statistically significant difference in postoperative paraplegia or stroke rate was noted between TEVAR and open repair (1.4% vs 2.3% [OR, 1.27; 95% CI, 0.59-2.70; P = .54] and 1% vs 0.5% [OR, 0.63; 95% CI, 0.18-2.18; P = .46]). Lower 30-day and 1-year mortality was noted in TEVAR (7.9% vs 20% [OR, 2.94; 95% CI, 1.92-4.49; P < .00001] and 8.7% vs 17% [OR, 2.11; 95% CI, 0.99-4.52; P = .05]). There was no difference in 5-year mortality (23% vs 17%; OR, 0.07; 95% CI, -0.07 to 0.20; P = .33). However, there was a higher rate of reintervention at 1 year in the endovascular group (0% vs 6%; OR, 0.17; 95% CI, 0.03-0.96; P = .04). CONCLUSIONS: TEVAR carries lower in-hospital mortality and provides satisfactory perioperative outcomes compared with open repair in traumatic ruptured thoracic aorta. It also provides a favorable 1-year survival at the expense of higher reintervention rates.
引用
- Harky A, Bleetman D, Chan JSK, et al. A systematic review and meta-analysis of endovascular versus open surgical repair for the traumatic ruptured thoracic aorta. J Vasc Surg. 2019. PMID: 31327611. doi:10.1016/j.jvs.2019.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。